Table 1.

Participants' demographics and adverse events following vaccination.

Variables/groups	Unvaccinated (n = 22)	Unvaccinated previously PCR+ (n = 13)	BNT162b2 one dose (n = 29)	BBIBP-CorV one dose (n = 21)	BNT162b2 two doses (n = 27)	BBIBP-CorV two doses (n = 24)	BNT162b2 booster dose (n = 15)
Age in years	25.18 (19.96, 30.41)	26.62 (18.67, 34.56)	28.14 (23.34, 32.94)	32.62 (26.55, 38.69)	29.96 (25.29, 34.63)	25.83 (23.01, 28.66)	23.67 (21.49, 25.84)
Gender
Males	45%	8%	52%	38%	63%	62%	20%
Females	55%	92%	48%	62%	37%	38%	80%
Height in centimeters	167.4 (163.4, 171.3)	164.7 (160.1, 169.2)	169.7 (166.3, 173.1)	167.2 (164.1, 170.4)	172.7 (168.7, 176.6)	173.3 (168.9, 177.6)	166.8 (162.6, 171.0)
Weight in kilograms	67.80 (61.34, 74.26)	66.31 (54.01, 78.60)	69.85 (64.07, 75.64)	67.00 (62.93, 71.07)	74.31 (66.73, 81.88)	72.25 (65.36, 79.14)	59.27 (55.05, 63.48)
Time since the latest infection or vaccine dose in days	NA	187.1 (133.3, 240.9)	34.34 (23.66, 45.03)	102.7 (82.87, 122.5)	113.4 (80.46, 146.4)	72.46 (60.47, 84.45)	67.07 (29.83, 104.3)
Local symptoms after vaccination (1) Pain (2) Swelling (3) Redness (4) Itch	NA	NA	(1) 73% (2) 19% (3) 8% (4) 15%	(1) 31% (2) 6% (3) 0% (4) 6%	(1) 90% (2) 0% (3) 0% (4) 10%	(1) 58% (2) 0% (3) 0% (4) 0%	(1) 87% (2) 0% (3) 7% (4)0%
Systemic symptoms after vaccination (1) Fever (2) Fatigue (3) Headache (4) Chills (5) Vomiting (6) Diarrhea (7) Muscle pain (8) Joint pain	NA	NA	(1) 23% (2) 42% (3) 29% (4) 4% (5) 0% (6) 0% (7) 42% (8) 12%	(1) 13% (2) 31% (3) 13% (4) 6% (5) 0% (6) 0% (7) 13% (8) 13%	(1) 25% (2) 65% (3) 30% (4) 10% (5) 0% (6) 5% (7) 45% (8) 35%	(1) 17% (2) 8% (3) 17% (4) 8% (5) 0% (6) 0% (7) 8% (8) 8%	(1) 33% (2) 40% (3) 27% (4) 27% (5) 0% (6) 0% (7) 20% (8) 13%

^aData is presented either as mean and (95% confidence intervals) or as a percent of participants.